TNSN96141A1 - Formulations pharmaceutiques et procede pour leur production - Google Patents
Formulations pharmaceutiques et procede pour leur productionInfo
- Publication number
- TNSN96141A1 TNSN96141A1 TNTNSN96141A TNSN96141A TNSN96141A1 TN SN96141 A1 TNSN96141 A1 TN SN96141A1 TN TNSN96141 A TNTNSN96141 A TN TNSN96141A TN SN96141 A TNSN96141 A TN SN96141A TN SN96141 A1 TNSN96141 A1 TN SN96141A1
- Authority
- TN
- Tunisia
- Prior art keywords
- formulation
- production
- pharmaceutical formulations
- administration
- hydroxypropylmethylcellulose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L’INVENTION CONCERNE UNE FORMULATION PHARMACEUTIQUE A LIBERATION CONTROLEE POUR L’ADMINISTRATION ORALE. CETTE FORMULATION CONSISTE EN UN COMPOSE MEDICAMENTEUX ACTIF, UN POLYMERE D’OXYDE D’ETHYLENE DE BAS POIDS MOLECULAIRE, DE L’HYDROXYPROPYLMETHYLCELLULOSE, DES EXCIPIENTS DE COMPRESSION ET, FACULTATIVEMENT, UN OU PLUSIEURS POLYMERES ENTERIQUES. APPLICATION : OBTENTION DE FORMULATION A VITESSE CONSTANTE DE LIBERATION POUR L'ADMINISTRATION DE DIVERS MEDICAMENTS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9523752.5A GB9523752D0 (en) | 1995-11-21 | 1995-11-21 | Pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN96141A1 true TNSN96141A1 (fr) | 2005-03-15 |
Family
ID=10784188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN96141A TNSN96141A1 (fr) | 1995-11-21 | 1996-11-20 | Formulations pharmaceutiques et procede pour leur production |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP0862437A1 (fr) |
JP (1) | JPH10513481A (fr) |
KR (1) | KR19990071505A (fr) |
CN (1) | CN1215993A (fr) |
AP (1) | AP718A (fr) |
AR (1) | AR004335A1 (fr) |
AU (1) | AU709560B2 (fr) |
BG (1) | BG102438A (fr) |
BR (1) | BR9611626A (fr) |
CA (1) | CA2232715A1 (fr) |
CO (1) | CO4480020A1 (fr) |
CZ (1) | CZ155498A3 (fr) |
GB (1) | GB9523752D0 (fr) |
HR (1) | HRP960554A2 (fr) |
HU (1) | HUP9903734A3 (fr) |
IS (1) | IS4706A (fr) |
MA (1) | MA26410A1 (fr) |
MX (1) | MX9804008A (fr) |
NO (1) | NO982302L (fr) |
NZ (1) | NZ322053A (fr) |
OA (1) | OA10687A (fr) |
PE (1) | PE22898A1 (fr) |
PL (1) | PL326981A1 (fr) |
SK (1) | SK63098A3 (fr) |
TN (1) | TNSN96141A1 (fr) |
TR (1) | TR199800902T2 (fr) |
WO (1) | WO1997018814A1 (fr) |
YU (1) | YU62096A (fr) |
ZA (1) | ZA969722B (fr) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU759825B2 (en) * | 1997-12-16 | 2003-05-01 | Pfizer Products Inc. | Combination effective for the treatment of impotence |
AU736951C (en) | 1998-03-19 | 2003-02-20 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
GT199900061A (es) * | 1998-05-15 | 2000-10-14 | Pfizer | Formulaciones farmaceuticas. |
EP0987020A1 (fr) * | 1998-09-04 | 2000-03-22 | Pharma Pass LLC | Composition contenant du metoprolol et procédé de préparation |
EP0974343B1 (fr) * | 1998-07-22 | 2004-09-29 | Pharma Pass II LLC | Procédé de préparation d'une composition solide contentant du metoprolol |
CO5140079A1 (es) * | 1998-10-14 | 2002-03-22 | Novartis Ag | Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo |
UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
US20030059467A1 (en) * | 2001-09-14 | 2003-03-27 | Pawan Seth | Pharmaceutical composition comprising doxasozin |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
WO2005037247A2 (fr) * | 2003-10-17 | 2005-04-28 | Ranbaxy Laboratories Limited | Formulations matricielles de doxazosine a administration orale |
US20050255157A1 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Sustained release, mucoadhesive vaginal pharmaceutical compositions |
KR100574554B1 (ko) * | 2004-05-28 | 2006-04-27 | 한미약품 주식회사 | 니아신의 경구투여용 서방성 조성물 |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
KR100679111B1 (ko) * | 2004-11-20 | 2007-02-07 | 대우약품공업주식회사 | 독사조신을 포함하는 서방성 정제 |
CA2619035A1 (fr) * | 2005-08-22 | 2007-03-01 | Novartis Ag | Compositions pharmaceutiques |
US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
CA2597740C (fr) | 2006-04-26 | 2012-10-16 | Supernus Pharmaceuticals, Inc. | Preparations a liberation modifiee contenant de l'oxcarbazepine et derives connexes |
CA2810839A1 (fr) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Polymorphes |
EP1852108A1 (fr) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Compositions d'inhibiteurs de la DPP IV |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
CN100396282C (zh) * | 2006-07-25 | 2008-06-25 | 山东省医药工业研究所 | 甲磺酸多沙唑嗪缓释胶囊及制备方法 |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
AU2009223061B2 (en) | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
KR101004205B1 (ko) | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
EP2395983B1 (fr) | 2009-02-13 | 2020-04-08 | Boehringer Ingelheim International GmbH | Composition pharmaceutique contenant un inhibiteur sglt2 en combinaison avec un inhibiteur dpp-iv et optioenellement un autre agent antidiabetique |
US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
EP2421524B1 (fr) | 2009-04-20 | 2018-08-08 | Elcelyx Therapeutics, Inc. | Thérapies à base de ligand de récepteur chimiosensible |
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
CN107115530A (zh) | 2009-11-27 | 2017-09-01 | 勃林格殷格翰国际有限公司 | 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗 |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
EP2590634B1 (fr) | 2010-07-09 | 2016-03-09 | BHV Pharma, Inc. | Système d'administration à libération immédiate/retardée en combinaison pour des médicaments à courte demi-vie comprenant de la rémogliflozine |
KR20140114736A (ko) | 2010-10-19 | 2014-09-29 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 화학감각 수용체 리간드-기반 요법 |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
HUE051738T2 (hu) | 2011-01-07 | 2021-03-29 | Anji Pharma Us Llc | Kemoszenzoros receptorligandum-alapú terápiák |
CN102058555A (zh) * | 2011-01-13 | 2011-05-18 | 北京汇诚瑞祥医药技术有限公司 | 一种多沙唑嗪控释片 |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
CN102188431A (zh) * | 2011-05-09 | 2011-09-21 | 浙江九旭药业有限公司 | 甲磺酸多沙唑嗪缓释片及其制备方法 |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013158928A2 (fr) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Thérapies à base de ligand de récepteur chimiosensoriels |
US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (fr) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires |
EP3003297A4 (fr) | 2013-06-05 | 2017-04-19 | Synchroneuron Inc. | Formulations d'acamprosate, procédés d'utilisation de celles-ci, et combinaisons comprenant celles-ci |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
CN105616378A (zh) * | 2014-10-31 | 2016-06-01 | 康普药业股份有限公司 | 一种氟康唑胶囊及其制备方法 |
CA3022202A1 (fr) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinaisons de linagliptine et de metformine |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1198386B (it) * | 1982-07-06 | 1988-12-21 | Lepetit Spa | Un prodotto a rilascio protratto contenente il suloctidile |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4837111A (en) * | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
NZ239033A (en) * | 1990-07-23 | 1994-04-27 | Alza Corp | Semipermeable capsule with a hole containing a nicotine salt which reacts with water to release nicotine base |
-
1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
-
1996
- 1996-11-11 BR BR9611626A patent/BR9611626A/pt not_active Application Discontinuation
- 1996-11-11 NZ NZ322053A patent/NZ322053A/xx unknown
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/ko not_active Application Discontinuation
- 1996-11-11 JP JP9519364A patent/JPH10513481A/ja active Pending
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/hu unknown
- 1996-11-11 CN CN96198486A patent/CN1215993A/zh active Pending
- 1996-11-11 EP EP96938215A patent/EP0862437A1/fr not_active Withdrawn
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/fr not_active Application Discontinuation
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/cs unknown
- 1996-11-11 CA CA002232715A patent/CA2232715A1/fr not_active Abandoned
- 1996-11-11 SK SK630-98A patent/SK63098A3/sk unknown
- 1996-11-11 PL PL96326981A patent/PL326981A1/xx unknown
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/xx unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/es not_active Application Discontinuation
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/xx unknown
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/fr unknown
- 1996-11-20 MA MA24397A patent/MA26410A1/fr unknown
- 1996-11-20 YU YU62096A patent/YU62096A/sh unknown
- 1996-11-20 AR ARP960105252A patent/AR004335A1/es unknown
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
- 1996-11-21 CO CO96061449A patent/CO4480020A1/es unknown
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/hr not_active Application Discontinuation
-
1998
- 1998-03-31 IS IS4706A patent/IS4706A/is unknown
- 1998-05-08 BG BG102438A patent/BG102438A/xx unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 NO NO982302A patent/NO982302L/no not_active Application Discontinuation
- 1998-05-20 MX MX9804008A patent/MX9804008A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP0862437A1 (fr) | 1998-09-09 |
NO982302D0 (no) | 1998-05-20 |
BG102438A (en) | 1999-01-29 |
YU62096A (sh) | 1999-03-04 |
AP9600883A0 (en) | 1997-01-31 |
JPH10513481A (ja) | 1998-12-22 |
PL326981A1 (en) | 1998-11-09 |
CN1215993A (zh) | 1999-05-05 |
GB9523752D0 (en) | 1996-01-24 |
OA10687A (en) | 2002-11-27 |
NZ322053A (en) | 1999-11-29 |
IS4706A (is) | 1998-03-31 |
ZA969722B (en) | 1998-05-20 |
AR004335A1 (es) | 1998-11-04 |
NO982302L (no) | 1998-07-17 |
AP718A (en) | 1999-01-06 |
HRP960554A2 (en) | 1998-02-28 |
WO1997018814A1 (fr) | 1997-05-29 |
TR199800902T2 (xx) | 1998-09-21 |
MA26410A1 (fr) | 2004-12-20 |
MX9804008A (es) | 1998-09-30 |
KR19990071505A (ko) | 1999-09-27 |
BR9611626A (pt) | 1999-06-01 |
CA2232715A1 (fr) | 1997-05-29 |
HUP9903734A2 (hu) | 2000-03-28 |
SK63098A3 (en) | 1999-05-07 |
AU709560B2 (en) | 1999-09-02 |
CO4480020A1 (es) | 1997-07-09 |
CZ155498A3 (cs) | 1999-03-17 |
AU7572196A (en) | 1997-06-11 |
HUP9903734A3 (en) | 2000-04-28 |
PE22898A1 (es) | 1998-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN96141A1 (fr) | Formulations pharmaceutiques et procede pour leur production | |
HUP9802339A2 (hu) | Darifenacint tartalmazó gyógyászati készítmények | |
WO1997015269A3 (fr) | Procede, compositions et kits destines a ameliorer la biodisponibilite par voie orale d'agents pharmaceutiques | |
WO1996039156A3 (fr) | Polymeres de liaison du phosphate pour administration par voie orale | |
CA2322644A1 (fr) | Composition pharmaceutique de topiramate | |
ATE293995T1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
HUP0400264A2 (hu) | Alacsony oldékonyságú és/vagy savra érzékeny hatóanyagokat és semlegesített savas polimereket tartalmazó gyógyszerkészítmények és eljárás az előállításukra | |
WO1995005184A3 (fr) | Polymeres fixant les phosphates pour administration orale | |
DK0991653T3 (da) | Nye forbindelser | |
HUP9702424A2 (hu) | Olvadékextrudált szilárd hatóanyag-készítmények | |
BR0013948A (pt) | Prodroga, composição farmacêutica, e, método de tratamento de um paciente mamìfero | |
DZ2923A1 (fr) | Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation. | |
HUP0003323A2 (hu) | Vorikonazolt tartalmazó gyógyászati készítmények | |
EP0108218A3 (fr) | Forme de dosage orale solide à libération constante de composés pharmaceutiques très solubles dans l'eau | |
HUP9901707A2 (hu) | Gasztrointesztinális rendellenességek megelőzésére és kezelésére szolgáló gyógyászati, és diétás készítmények | |
MY124599A (en) | Oral suspension of pharmaceutical substance | |
CA2285037A1 (fr) | Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant | |
RU2001110355A (ru) | Независящие от влияния пищи фармацевтические дозированные препаративные формы пролонгированного действия, содержащие множество единиц, и способ их получения | |
NZ510563A (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
DE69716586T2 (de) | Gepufferte orthoesterpolymere enthaltende arzneimittel | |
KR910009241A (ko) | 치근막 질환 치료용 서방성 조성물 | |
DZ3048A1 (fr) | Précurseurs médicamenteux mutuels d'amlopidine et d'atorvastine, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
CA2219777A1 (fr) | Nanoparticules pour l'administration orale d'agents pharmaceutiques de faible solubilite | |
TR200101163T2 (tr) | Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları | |
DZ3103A1 (fr) | Nouvelles pyrazolo Ä4,3-EÜdiazépines substituées, compositions pharmaceutiques les contenant, utili sation à titre de médicament et procédés pour leurs préparation. |